Combined targeting of mammalian target of rapamycin (mTOR) signaling and VEGF/NRP1 using a liposomal formulation decorated with a proprietary tumor-targeting peptide that simultaneously delivers the mTOR inhibitor everolimus and the NRP1 inhibitor EG00229 reduces the growth of experimental clear cell renal cell carcinoma and related lung metastases [65]. This evidence concerns the gene NRP1 and neoplasm.